Article Versions Notes

Taylor K, Williamson J, Luther V, Stone T, Johnson J, Gruss Z, Russ-Friedman C, Ohl C, Beardsley J. Evaluating the Use of Dalbavancin for Off-Label Indications. Infectious Disease Reports. 2022; 14(2):266-272. https://doi.org/10.3390/idr14020032

Taylor, Katherine, John Williamson, Vera Luther, Tyler Stone, James Johnson, Zachary Gruss, Courtney Russ-Friedman, Chris Ohl, and James Beardsley. 2022. "Evaluating the Use of Dalbavancin for Off-Label Indications" Infectious Disease Reports 14, no. 2: 266-272. https://doi.org/10.3390/idr14020032

Taylor, K., Williamson, J., Luther, V., Stone, T., Johnson, J., Gruss, Z., Russ-Friedman, C., Ohl, C., & Beardsley, J. (2022). Evaluating the Use of Dalbavancin for Off-Label Indications. Infectious Disease Reports, 14(2), 266-272. https://doi.org/10.3390/idr14020032